GlassScriptPhysician profile
Daniel J Minkin
NPI 1740281757
$4,842.89
in general payments reported to CMS, 2019-2025
34 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $421 · 2021: $693 · 2022: $827 · 2023: $732 · 2024: $598 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.57 |
| Education | $111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.55 | 2019-2025 | |
| Astellas Pharma US INC | $533.48 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $435.35 | 2021-2025 | |
| Exeltis, USA INC. | $316.57 | 2019-2025 | Slynd |
| Pfizer INC. | $279.03 | 2019-2023 | |
| Therapeuticsmd, INC. | $271.19 | 2019-2022 | |
| Caldera Medical, INC | $222.73 | 2025 | |
| Evofem Biosciences, INC. | $210.15 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $195.54 | 2019-2025 | |
| Coopersurgical, INC. | $174.78 | 2019-2025 | Paragard T 380a, Mara Console, Paragard T 380a |
| Sage Therapeutics, LLC | $149.67 | 2022-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $138.56 | 2020-2025 | Aptima |
| Myovant Sciences INC. | $128.30 | 2021-2022 | |
| Shield Therapeutics INC | $121.73 | 2024-2025 | |
| Amgen INC. | $110.40 | 2019-2023 | Evenity, Prolia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $105.17 | 2019-2024 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $102.23 | 2019-2023 | Gardasil 9 |
| Allergan, INC. | $91.10 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $89.52 | 2024-2025 | Myfembree, Gemtesa |
| Amag Pharmaceuticals, INC. | $79.50 | 2019-2020 | |
| Alydia Health | $66.49 | 2021 | |
| Dysis Medical, INC. | $62.21 | 2019 | |
| Avion Pharmaceuticals | $57.17 | 2019-2021 | |
| Scynexis, INC. | $54.38 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $54.28 | 2021-2022 | |
| Organon LLC | $38.54 | 2021-2022 | |
| Lupin INC. | $35.67 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $31.51 | 2025 | Qelbree |
| Urovant Sciences INC | $21.11 | 2022 | |
| Roche Diagnostics Corporation | $20.36 | 2019 | |
| Medtronic, INC. | $19.76 | 2024 | Ligasure |
| Exact Sciences Corporation | $18.59 | 2023 | Cologuard Collection Kit |
| Sanara Medtech INC. | $18.55 | 2023 | Celleraterx |
| Aspira Women'S Health INC | $16.72 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Minkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.